FDA Advisory Committee Recommends approval of new Alzheimer’s drug Donanemab

If approved, donanemab would be the third FDA approved disease-modifying beta-amyloid treatment for Alzheimer’s disease.

The post FDA Advisory Committee Recommends approval of new Alzheimer’s drug Donanemab first appeared on Science-Based Medicine.

from Science-Based Medicine https://sciencebasedmedicine.org/fda-advisory-committee-recommends-approval-of-new-alzheimers-drug-donanemab/?utm_source=rss&utm_medium=rss&utm_campaign=fda-advisory-committee-recommends-approval-of-new-alzheimers-drug-donanemab